BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $11.75 billion. The enterprise value is $10.60 billion.
| Market Cap | 11.75B |
| Enterprise Value | 10.60B |
Important Dates
The last earnings date was Monday, February 23, 2026, after market close.
| Earnings Date | Feb 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 192.32 million shares outstanding. The number of shares has increased by 0.35% in one year.
| Current Share Class | 192.32M |
| Shares Outstanding | 192.32M |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 98.63% |
| Float | 191.45M |
Valuation Ratios
The trailing PE ratio is 33.87 and the forward PE ratio is 11.45. BMRN's PEG ratio is 0.43.
| PE Ratio | 33.87 |
| Forward PE | 11.45 |
| PS Ratio | 3.58 |
| Forward PS | 3.28 |
| PB Ratio | 1.91 |
| P/TBV Ratio | 2.06 |
| P/FCF Ratio | 15.89 |
| P/OCF Ratio | 13.91 |
| PEG Ratio | 0.43 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.67, with an EV/FCF ratio of 14.62.
| EV / Earnings | 30.39 |
| EV / Sales | 3.29 |
| EV / EBITDA | 14.67 |
| EV / EBIT | 16.29 |
| EV / FCF | 14.62 |
Financial Position
The company has a current ratio of 5.21, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.21 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.88 |
| Debt / FCF | 0.89 |
| Interest Coverage | 59.71 |
Financial Efficiency
Return on equity (ROE) is 5.94% and return on invested capital (ROIC) is 9.09%.
| Return on Equity (ROE) | 5.94% |
| Return on Assets (ROA) | 5.58% |
| Return on Invested Capital (ROIC) | 9.09% |
| Return on Capital Employed (ROCE) | 9.52% |
| Weighted Average Cost of Capital (WACC) | 5.42% |
| Revenue Per Employee | $1.00M |
| Profits Per Employee | $108,321 |
| Employee Count | 3,221 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 0.47 |
Taxes
In the past 12 months, BMRN has paid $133.58 million in taxes.
| Income Tax | 133.58M |
| Effective Tax Rate | 27.69% |
Stock Price Statistics
The stock price has decreased by -13.98% in the last 52 weeks. The beta is 0.26, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -13.98% |
| 50-Day Moving Average | 59.07 |
| 200-Day Moving Average | 56.60 |
| Relative Strength Index (RSI) | 55.38 |
| Average Volume (20 Days) | 2,436,693 |
Short Selling Information
The latest short interest is 8.62 million, so 4.48% of the outstanding shares have been sold short.
| Short Interest | 8.62M |
| Short Previous Month | 7.91M |
| Short % of Shares Out | 4.48% |
| Short % of Float | 4.50% |
| Short Ratio (days to cover) | 3.99 |
Income Statement
In the last 12 months, BMRN had revenue of $3.22 billion and earned $348.90 million in profits. Earnings per share was $1.80.
| Revenue | 3.22B |
| Gross Profit | 2.62B |
| Operating Income | 650.73M |
| Pretax Income | 482.48M |
| Net Income | 348.90M |
| EBITDA | 722.89M |
| EBIT | 650.73M |
| Earnings Per Share (EPS) | $1.80 |
Balance Sheet
The company has $1.56 billion in cash and $642.87 million in debt, with a net cash position of $917.74 million or $4.77 per share.
| Cash & Cash Equivalents | 1.56B |
| Total Debt | 642.87M |
| Net Cash | 917.74M |
| Net Cash Per Share | $4.77 |
| Equity (Book Value) | 6.09B |
| Book Value Per Share | 31.65 |
| Working Capital | 3.19B |
Cash Flow
In the last 12 months, operating cash flow was $827.99 million and capital expenditures -$103.04 million, giving a free cash flow of $724.96 million.
| Operating Cash Flow | 827.99M |
| Capital Expenditures | -103.04M |
| Free Cash Flow | 724.96M |
| FCF Per Share | $3.77 |
Margins
Gross margin is 81.43%, with operating and profit margins of 20.20% and 10.83%.
| Gross Margin | 81.43% |
| Operating Margin | 20.20% |
| Pretax Margin | 14.98% |
| Profit Margin | 10.83% |
| EBITDA Margin | 22.44% |
| EBIT Margin | 20.20% |
| FCF Margin | 22.51% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.35% |
| Shareholder Yield | -0.35% |
| Earnings Yield | 3.03% |
| FCF Yield | 6.29% |
Analyst Forecast
The average price target for BMRN is $87.38, which is 42.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $87.38 |
| Price Target Difference | 42.97% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 11.93% |
| EPS Growth Forecast (5Y) | 40.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 5.77 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.77 |
| Piotroski F-Score | 6 |